摘要:
Compounds are provided according to formula 1: where A, B, W, X′, L, R1, R3, R4b, and m′ are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
摘要:
The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
摘要:
1. Use of (v) a gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vi) a transcription product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vii) a translation product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (viii) a fragment, or derivative, or variant of (i) to (iii). for identifying or for testing agents for the treatment and/or prevention of neurodegenerative diseases.
摘要翻译:1.(v)编码具有SEQ ID NO:1或SEQ ID NO:2的蛋白质磷酸酶1E的基因的使用,和/或(vi)编码具有SEQ ID NO:1或SEQ ID NO:2的蛋白质磷酸酶1E的基因的转录产物 和/或(vii)编码具有SEQ ID NO:1或SEQ ID NO:2的蛋白质磷酸酶1E的基因的翻译产物,和/或(viii)编码SEQ ID NO:1或SEQ ID NO: 片段或衍生物,或(i)至(iii)的变体。 用于鉴定或测试用于治疗和/或预防神经变性疾病的药剂。
摘要:
Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
摘要:
The invention relates to compounds of formula (I) wherein A, Y, Z1, Z2, R1 to R3 and X1 to X4 have the meaning as cited in the description and the claims. For example A is 4′-fluorobiphen-4-yl; Y is —S(O)2NH—; R1, R2 are H; X1, X2, X4 are CH; X3 is C—F; Z1 is ═O; and Z2-R3 is N(CH2CH3)2. Said compounds are useful as 11β-HSD1 inhibitors. The invention also relates to the preparation of such compounds as well as the production and use as medicament.
摘要:
The invention relates to virus like particles, their preparation and their use in pharmaceutical screening and functional genomics. The invention further provides a variety of assay formats to be used with said virus like particles.
摘要:
In a method for correcting for the size and/or shape of a measuring volume (18)in a chemical and/or biological sample (14), especially in fluorescence spectroscopy, a measuring volume (18) located within the sample (14) is imaged to a detector means (44), using observing optics (32). The imaging is effected through a sample carrier w all (16) of a sample carrier (12) containing the sample (14). In the next step, the thickness of the sample carrier wall (16) is automatically determined. Thereafter, at least one lens (28) is shifted automatically along an optical axis of the observing optics (32) to correct for the size and/or shape of the measuring volume (18) as a function of the thickness of the sample carrier wall (16).
摘要:
The invention relates to oxazine derivatives by means of which a broad spectrum of material to be examined can be marked and identified using fluorescence techniques.
摘要:
The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
摘要:
A method for analyzing chemical and/or biological samples comprises the production of a particle image (42) of at least one particle included in the sample. Subsequently, a particle surface (10) of the at least one particle included in the particle image (42) is divided into particle zones (14,18). According to the invention, zone-dependent particle data are subsequently acquired in different states (z1, z2, z3), which then can be evaluated.